HiFiBiO Therapeutics provides a Drug Intelligence Science (DIS®) platform that combines proprietary high‑fidelity single‑cell sequencing and phenotyping with AI/ML analytics to identify therapeutic targets, generate lead antibodies, and predict biomarkers for immunotherapies. The end‑to‑end workflow delivers over 10,000 cell profiles per assay and real‑time functional readouts, enabling pharmaceutical and biotech partners to accelerate candidate selection and IND filing.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery, especially for immunotherapies, suffers from low hit rates and long timelines because conventional screening methods lack the resolution to capture cellular heterogeneity and predictive biomarkers, leading to high attrition in clinical development.
Solution
HiFiBiO Therapeutics addresses this gap with its Drug Intelligence Science (DIS®) platform, which combines proprietary high‑fidelity single‑cell screening with AI/ML analytics to map disease‑relevant cellular states. The platform enables rapid target discovery, antibody selection, and predictive biomarker identification across multiple disease areas, accelerating the transition from candidate selection to IND filing. By generating functional, high‑throughput data at single‑cell resolution, DIS® improves the probability of clinical success for curative immunotherapies. The resulting candidates are advanced through preclinical and early‑stage clinical programs, supported by a growing network of strategic partnerships.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing immunotherapies, as well as academic research institutions seeking high‑resolution target validation and biomarker discovery capabilities.
Features
- Proprietary single‑cell sequencing and phenotyping pipeline delivering >10,000 cell profiles per assay
- Integrated AI/ML models that infer cellular pathways, prioritize therapeutic targets, and predict response biomarkers
- Automated antibody discovery workflow linking target validation to lead antibody generation
- Predictive biomarker panel generation for patient stratification and companion diagnostic development
- High‑throughput functional screening platform that evaluates cytokine release, cytotoxicity, and signaling in real time
- End‑to‑end data management system with secure cloud storage and API access for partner integration
- Scalable workflow supporting multiple therapeutic modalities, including checkpoint inhibitors and cellular therapies
- Established pipeline of eight clinical candidates and a track record of four completed Phase I dose‑escalation trials